Wells Fargo Upgrades Iovance Biotherapeutics to Overweight, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Yanan Zhu upgraded Iovance Biotherapeutics (NASDAQ:IOVA) from Equal-Weight to Overweight and raised the price target from $11 to $17.
May 30, 2023 | 3:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iovance Biotherapeutics (NASDAQ:IOVA) has been upgraded to Overweight by Wells Fargo, with a raised price target of $17.
The upgrade from Equal-Weight to Overweight and the raised price target from $11 to $17 by Wells Fargo analyst Yanan Zhu indicate a positive outlook for Iovance Biotherapeutics. This news is likely to have a positive short-term impact on the stock price, as it reflects increased confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100